Back to Semaglutide research
semaglutide glp 1 agonist rct 2021-09-13 ClinicalTrials

Oral Semaglutide 50mg Shows Significant Weight Loss for Overweight and Obesity

Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1)

Background

Obesity and overweight are global health challenges requiring effective and accessible treatment strategies. While semaglutide tablets are already approved at lower doses for type 2 diabetes, their efficacy and safety at a higher oral dose specifically for weight loss in individuals without diabetes remained less explored. This pivotal study, OASIS 1, aimed to evaluate the effectiveness of a higher-dose oral semaglutide formulation for comprehensive weight management in people living with overweight or obesity.


semaglutide glp 1 agonist glp-1r dose mentioned protocol relevant
Source: clinicaltrials:NCT05035095 · Ingested 2026-04-03 · Digest: gemini-2.5-flash